Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

This study has been completed.

Sponsor:

Information provided by (Responsible Party):

Gilead Sciences

ClinicalTrials.gov Identifier:

NCT01095796

First received: March 17, 2010

Last updated: October 15, 2015

Last verified: October 2015

History of Changes

Results First Received: September 20, 2012

Study Type:	Interventional
Study Design:	Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor); Primary Purpose: Treatment
Conditions:	HIV HIV Infections
Interventions:	Drug: Stribild Drug: Atripla Drug: Stribild Placebo Drug: Atripla Placebo

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Participants were enrolled at sites in the United States and Puerto Rico. The first participant was screened on 16 March 2010. The last study visit occurred on 02 September 2014.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
917 participants were screened.

Reporting Groups

	Description
Stribild	Stribild® (elvitegravir (EVG) 150 mg/cobicistat (COBI) 150 mg/emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg) single-tablet regimen (STR) once daily plus placebo to match Atripla once daily prior to bedtime
Atripla	Atripla® (efavirenz (EFV) 600 mg/FTC 200 mg/TDF 300 mg) tablet once daily prior to bedtime plus placebo to match Stribild once daily

Participant Flow: Overall Study

	Stribild	Atripla
STARTED	353	354
COMPLETED	58	65
NOT COMPLETED	295	289
Randomized but Not Treated	5	2
Adverse Event	9	19
Death	3	2
Pregnancy	2	0
Lack of Efficacy	5	3
Investigator's Discretion	7	2
Withdrew Consent	16	22
Lost to Follow-up	27	29
Participant Noncompliance	5	10
Protocol Violation	1	0
Participant Transferred to Another Study	215	200

Baseline Characteristics

Hide Baseline Characteristics

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Safety Analysis Set: participants were randomized and received at least one dose of study medication.

Reporting Groups

	Description
Stribild	Stribild (EVG 150 mg/COBI 150 mg/FTC 200 mg/TDF 300 mg) STR once daily plus placebo to match Atripla once daily prior to bedtime
Atripla	Atripla (EFV 600 mg/FTC 200 mg/TDF 300 mg) tablet once daily prior to bedtime plus placebo to match Stribild once daily
Total	Total of all reporting groups

Baseline Measures

	Stribild	Atripla	Total
Overall Participants Analyzed [Units: Participants]	348	352	700

Age [Units: Years] Mean (Standard Deviation)	38 (10.4)	38 (10.6)	38 (10.5)

Gender [Units: Participants]
Female	41	36	77
Male	307	316	623

Race/Ethnicity, Customized [Units: Participants]
American Indian or Alaska Native	2	4	6
Asian	6	10	16
Black or African Heritage	106	91	197
Native Hawaiian or Pacific Islander	4	1	5
White	214	227	441
Other	16	19	35

Region of Enrollment [Units: Participants]
United States	348	352	700

HIV Disease Status [Units: Participants]
Asymptomatic	290	295	585
Symptomatic HIV Infections	30	33	63
AIDS	28	24	52

Hepatitis B Virus (HBV) Infection Status [Units: Participants]
Negative	343	343	686
Positive	5	9	14

Hepatitis C Virus (HCV) Infection Status [Units: Participants]
Negative	331	337	668
Positive	17	15	32

HIV-1 RNA Category (copies/mL) [Units: Participants]
≤ 100,000	230	236	466
> 100,000	118	116	234

CD4 Cell Count (/µL) [Units: Participants]
≤ 50	7	6	13
51 to ≤ 200	36	45	81
201 to ≤ 350	112	96	208
351 to ≤ 500	113	136	249
> 500	80	69	149

Outcome Measures

Show All Outcome Measures

1. Primary:

The Percentage of Participants With Virologic Success Using the Food and Drug Administration (FDA)-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 Ribonucleic Acid (RNA) < 50 Copies/mL at Week 48 [ Time Frame: Week 48 ]

Show Outcome Measure 1

2. Secondary:

The Percentage of Participants With Virologic Success Using the FDA-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 RNA < 50 Copies/mL at Week 96 [ Time Frame: Week 96 ]

Show Outcome Measure 2

3. Secondary:

The Percentage of Participants With Virologic Success Using the FDA-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 RNA < 50 Copies/mL at Week 144 [ Time Frame: Week 144 ]

Show Outcome Measure 3

4. Secondary:

The Percentage of Participants With Virologic Success Using the FDA-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 RNA < 50 Copies/mL at Week 192 [ Time Frame: Week 192 ]

Show Outcome Measure 4

5. Secondary:

The Percentage of Participants Achieving and Maintaining Confirmed HIV-1 RNA < 50 Copies/mL at Week 48 Using the FDA-defined Time to Loss of Virologic Response (TLOVR) Algorithm [ Time Frame: Week 48 ]

Show Outcome Measure 5

6. Secondary:

The Change From Baseline in Cluster Determinant 4 (CD4) Cell Count at Weeks 48, 96, 144, and 192 [ Time Frame: Baseline; Weeks 48, 96, 144, and 192 ]

Show Outcome Measure 6

7. Secondary:

The Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 [ Time Frame: Week 48 ]

Show Outcome Measure 7

Serious Adverse Events

Hide Serious Adverse Events

Time Frame	Up to 218 weeks plus 30 days
Additional Description	Safety Analysis Set: participants were randomized and received at least one dose of study drug.

Reporting Groups

	Description
Stribild	Stribild (EVG 150 mg/COBI 150 mg/FTC 200 mg/TDF 300 mg) STR once daily plus placebo to match Atripla once daily prior to bedtime
Atripla	Atripla (EFV 600 mg/FTC 200 mg/TDF 300 mg) tablet once daily prior to bedtime plus placebo to match Stribild once daily

Serious Adverse Events

	Stribild	Atripla
Total, Serious Adverse Events
# participants affected / at risk	69/348 (19.83%)	50/352 (14.20%)
Blood and lymphatic system disorders
Anaemia ^† 1
# participants affected / at risk	0/348 (0.00%)	1/352 (0.28%)
Antiphospholipid syndrome ^† 1
# participants affected / at risk	0/348 (0.00%)	1/352 (0.28%)
Splenic vein thrombosis ^† 1
# participants affected / at risk	0/348 (0.00%)	1/352 (0.28%)
Thrombocytopenia ^† 1
# participants affected / at risk	0/348 (0.00%)	1/352 (0.28%)
Cardiac disorders
Acute myocardial infarction ^† 1
# participants affected / at risk	0/348 (0.00%)	1/352 (0.28%)
Bradycardia ^† 1
# participants affected / at risk	0/348 (0.00%)	1/352 (0.28%)
Intracardiac mass ^† 1
# participants affected / at risk	0/348 (0.00%)	1/352 (0.28%)
Palpitations ^† 1
# participants affected / at risk	0/348 (0.00%)	1/352 (0.28%)
Supraventricular tachycardia ^† 1
# participants affected / at risk	0/348 (0.00%)	1/352 (0.28%)
Tachycardia ^† 1
# participants affected / at risk	0/348 (0.00%)	1/352 (0.28%)
Gastrointestinal disorders
Abdominal pain ^† 1
# participants affected / at risk	1/348 (0.29%)	2/352 (0.57%)
Colitis ^† 1
# participants affected / at risk	2/348 (0.57%)	0/352 (0.00%)
Diarrhoea ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Gastritis ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Haematemesis ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Inflammatory bowel disease ^† 1
# participants affected / at risk	0/348 (0.00%)	1/352 (0.28%)
Inguinal hernia ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Intestinal mass ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Intestinal perforation ^† 1
# participants affected / at risk	1/348 (0.29%)	1/352 (0.28%)
Mesenteric vein thrombosis ^† 1
# participants affected / at risk	0/348 (0.00%)	1/352 (0.28%)
Pancreatitis ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Pancreatitis acute ^† 1
# participants affected / at risk	0/348 (0.00%)	1/352 (0.28%)
Proctalgia ^† 1
# participants affected / at risk	2/348 (0.57%)	0/352 (0.00%)
Umbilical hernia ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Upper gastrointestinal haemorrhage ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Vomiting ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
General disorders
Asthenia ^† 1
# participants affected / at risk	0/348 (0.00%)	1/352 (0.28%)
Chest pain ^† 1
# participants affected / at risk	1/348 (0.29%)	1/352 (0.28%)
Fatigue ^† 1
# participants affected / at risk	2/348 (0.57%)	0/352 (0.00%)
Non-cardiac chest pain ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Pyrexia ^† 1
# participants affected / at risk	1/348 (0.29%)	2/352 (0.57%)
Systemic inflammatory response syndrome ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Hepatobiliary disorders
Cholecystitis ^† 1
# participants affected / at risk	1/348 (0.29%)	1/352 (0.28%)
Cholelithiasis ^† 1
# participants affected / at risk	2/348 (0.57%)	0/352 (0.00%)
Hepatitis alcoholic ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Liver injury ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Immune system disorders
Anaphylactic reaction ^† 1
# participants affected / at risk	0/348 (0.00%)	1/352 (0.28%)
Infections and infestations
Abscess limb ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Acute sinusitis ^† 1
# participants affected / at risk	0/348 (0.00%)	1/352 (0.28%)
Appendicitis ^† 1
# participants affected / at risk	4/348 (1.15%)	3/352 (0.85%)
Bronchitis ^† 1
# participants affected / at risk	1/348 (0.29%)	3/352 (0.85%)
Bronchitis bacterial ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Cellulitis ^† 1
# participants affected / at risk	6/348 (1.72%)	0/352 (0.00%)
Cellulitis staphylococcal ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Diarrhoea infectious ^† 1
# participants affected / at risk	0/348 (0.00%)	1/352 (0.28%)
Diverticulitis ^† 1
# participants affected / at risk	1/348 (0.29%)	1/352 (0.28%)
Gastroenteritis ^† 1
# participants affected / at risk	2/348 (0.57%)	1/352 (0.28%)
Giardiasis ^† 1
# participants affected / at risk	0/348 (0.00%)	1/352 (0.28%)
H1N1 influenza ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Herpes simplex ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Incision site infection ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Meningitis viral ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Muscle abscess ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Neurosyphilis ^† 1
# participants affected / at risk	1/348 (0.29%)	2/352 (0.57%)
Ovarian abscess ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Pelvic inflammatory disease ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Pneumonia ^† 1
# participants affected / at risk	9/348 (2.59%)	2/352 (0.57%)
Pneumonia legionella ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Pulmonary tuberculosis ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Pyelonephritis acute ^† 1
# participants affected / at risk	0/348 (0.00%)	1/352 (0.28%)
Rectal abscess ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Secondary syphilis ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Sepsis ^† 1
# participants affected / at risk	0/348 (0.00%)	1/352 (0.28%)
Sepsis syndrome ^† 1
# participants affected / at risk	0/348 (0.00%)	1/352 (0.28%)
Skin bacterial infection ^† 1
# participants affected / at risk	0/348 (0.00%)	1/352 (0.28%)
Subcutaneous abscess ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Urinary tract infection ^† 1
# participants affected / at risk	0/348 (0.00%)	1/352 (0.28%)
Viral infection ^† 1
# participants affected / at risk	3/348 (0.86%)	0/352 (0.00%)
Injury, poisoning and procedural complications
Ankle fracture ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Cervical vertebral fracture ^† 1
# participants affected / at risk	0/348 (0.00%)	1/352 (0.28%)
Facial bones fracture ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Femur fracture ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Fibula fracture ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Gun shot wound ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Head injury ^† 1
# participants affected / at risk	0/348 (0.00%)	1/352 (0.28%)
Humerus fracture ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Intentional overdose ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Joint dislocation ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Limb injury ^† 1
# participants affected / at risk	0/348 (0.00%)	1/352 (0.28%)
Lumbar vertebral fracture ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Post procedural haemorrhage ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Subdural haematoma ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Tibia fracture ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Investigations
Alanine aminotransferase increased ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Aspartate aminotransferase increased ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Transaminases increased ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Metabolism and nutrition disorders
Dehydration ^† 1
# participants affected / at risk	0/348 (0.00%)	2/352 (0.57%)
Diabetic ketoacidosis ^† 1
# participants affected / at risk	0/348 (0.00%)	1/352 (0.28%)
Musculoskeletal and connective tissue disorders
Arthritis ^† 1
# participants affected / at risk	0/348 (0.00%)	1/352 (0.28%)
Back pain ^† 1
# participants affected / at risk	0/348 (0.00%)	1/352 (0.28%)
Intervertebral disc protrusion ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Synovitis ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenocarcinoma ^† 1
# participants affected / at risk	0/348 (0.00%)	1/352 (0.28%)
Anal cancer ^† 1
# participants affected / at risk	0/348 (0.00%)	1/352 (0.28%)
Anal cancer recurrent ^† 1
# participants affected / at risk	0/348 (0.00%)	1/352 (0.28%)
Anorectal human papilloma virus infection ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Bladder cancer recurrent ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Burkitt's lymphoma ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Colorectal cancer stage IV ^† 1
# participants affected / at risk	0/348 (0.00%)	1/352 (0.28%)
Diffuse large B-cell lymphoma ^† 1
# participants affected / at risk	0/348 (0.00%)	1/352 (0.28%)
Hodgkin's disease ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Immune reconstitution inflammatory syndrome associated Kaposi's sarcoma ^† 1
# participants affected / at risk	0/348 (0.00%)	1/352 (0.28%)
Kaposi's sarcoma ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Lymphoma ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Malignant melanoma ^† 1
# participants affected / at risk	0/348 (0.00%)	1/352 (0.28%)
Metastatic neoplasm ^† 1
# participants affected / at risk	0/348 (0.00%)	1/352 (0.28%)
Uterine leiomyoma ^† 1
# participants affected / at risk	2/348 (0.57%)	1/352 (0.28%)
Nervous system disorders
Convulsion ^† 1
# participants affected / at risk	0/348 (0.00%)	1/352 (0.28%)
Grand mal convulsion ^† 1
# participants affected / at risk	0/348 (0.00%)	1/352 (0.28%)
Headache ^† 1
# participants affected / at risk	1/348 (0.29%)	1/352 (0.28%)
Hepatic encephalopathy ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Migraine ^† 1
# participants affected / at risk	1/348 (0.29%)	1/352 (0.28%)
Presyncope ^† 1
# participants affected / at risk	0/348 (0.00%)	1/352 (0.28%)
Syncope ^† 1
# participants affected / at risk	1/348 (0.29%)	2/352 (0.57%)
Psychiatric disorders
Alcoholism ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Bipolar disorder ^† 1
# participants affected / at risk	1/348 (0.29%)	1/352 (0.28%)
Completed suicide ^† 1
# participants affected / at risk	1/348 (0.29%)	2/352 (0.57%)
Depression ^† 1
# participants affected / at risk	2/348 (0.57%)	1/352 (0.28%)
Depression suicidal ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Drug dependence ^† 1
# participants affected / at risk	0/348 (0.00%)	1/352 (0.28%)
Major depression ^† 1
# participants affected / at risk	0/348 (0.00%)	1/352 (0.28%)
Psychotic disorder ^† 1
# participants affected / at risk	0/348 (0.00%)	1/352 (0.28%)
Suicidal behaviour ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Suicidal ideation ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Suicide attempt ^† 1
# participants affected / at risk	1/348 (0.29%)	2/352 (0.57%)
Renal and urinary disorders
Nephrolithiasis ^† 1
# participants affected / at risk	0/348 (0.00%)	2/352 (0.57%)
Renal failure ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Renal failure acute ^† 1
# participants affected / at risk	0/348 (0.00%)	1/352 (0.28%)
Reproductive system and breast disorders
Pelvic pain ^† 1
# participants affected / at risk	0/348 (0.00%)	1/352 (0.28%)
Testicular mass ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Respiratory, thoracic and mediastinal disorders
Asthma ^† 1
# participants affected / at risk	3/348 (0.86%)	1/352 (0.28%)
Chronic obstructive pulmonary disease ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Dyspnoea ^† 1
# participants affected / at risk	0/348 (0.00%)	2/352 (0.57%)
Dyspnoea exertional ^† 1
# participants affected / at risk	0/348 (0.00%)	1/352 (0.28%)
Pleural effusion ^† 1
# participants affected / at risk	0/348 (0.00%)	1/352 (0.28%)
Pneumomediastinum ^† 1
# participants affected / at risk	0/348 (0.00%)	1/352 (0.28%)
Pulmonary embolism ^† 1
# participants affected / at risk	0/348 (0.00%)	1/352 (0.28%)
Pulmonary thrombosis ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Respiratory failure ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Skin and subcutaneous tissue disorders
Rash maculo-papular ^† 1
# participants affected / at risk	0/348 (0.00%)	1/352 (0.28%)
Social circumstances
Alcohol use ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)
Vascular disorders
Deep vein thrombosis ^† 1
# participants affected / at risk	2/348 (0.57%)	0/352 (0.00%)
Haematoma ^† 1
# participants affected / at risk	0/348 (0.00%)	1/352 (0.28%)
Hypertension ^† 1
# participants affected / at risk	2/348 (0.57%)	0/352 (0.00%)
Hypertensive crisis ^† 1
# participants affected / at risk	1/348 (0.29%)	0/352 (0.00%)

†	Events were collected by systematic assessment
1	Term from vocabulary, MedDRA 17.0

Other Adverse Events

Show Other Adverse Events

Limitations and Caveats

Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
There were no limitations affecting the analysis or results.

More Information

Hide More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

The agreement is:

The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.

The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.

Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.

Restriction Description:

After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:

The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or
The study has been completed at all study sites for at least 2 years

Results Point of Contact:

Name/Title: Clinical Trial Disclosures
Organization: Gilead Sciences, Inc.
e-mail: ClinicalTrialDisclosures@gilead.com

Publications of Results:

Sax PE, DeJesus E, Mills A, Zolopa A, Cohen C, Wohl D, Gallant JE, Liu HC, Zhong L, Yale K, White K, Kearney BP, Szwarcberg J, Quirk E, Cheng AK; GS-US-236-0102 study team. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet. 2012 Jun 30;379(9835):2439-48. doi: 10.1016/S0140-6736(12)60917-9. Erratum in: Lancet. 2012 Aug 25;380(9843):730.

Zolopa A, Sax PE, DeJesus E, Mills A, Cohen C, Wohl D, Gallant JE, Liu HC, Plummer A, White KL, Cheng AK, Rhee MS, Szwarcberg J; GS-US-236-0102 Study Team. A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr. 2013 May 1;63(1):96-100. doi: 10.1097/QAI.0b013e318289545c.

Wohl DA, Cohen C, Gallant JE, Mills A, Sax PE, Dejesus E, Zolopa A, Liu HC, Plummer A, White KL, Cheng AK, Rhee MS, Szwarcberg J; GS-US-236-0102 Study Team. A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr. 2014 Mar 1;65(3):e118-20. doi: 10.1097/QAI.0000000000000057.

Responsible Party:	Gilead Sciences
ClinicalTrials.gov Identifier:	NCT01095796 History of Changes
Other Study ID Numbers:	GS-US-236-0102
Study First Received:	March 17, 2010
Results First Received:	September 20, 2012
Last Updated:	October 15, 2015

To Top